We're spending billions to treat diseases that are secondary effects of a primary state we haven't defined. That primary state is aging itself, and our failure to characterize it independently of pathology is why interventions keep failing in translation.

The hypothesis: Physiological aging and pathological aging are distinct epigenetic and proteostatic trajectories that diverge in mid-life. We only ever study the latter, because it's what fills clinics and biobanks.

I'm proposing the Nonagenarian Null-Phenotype (NNP) Project. A multi-omic profiling initiative (transcriptomic, epigenetic, proteomic, metabolomic) focused exclusively on individuals over 90 who meet strict criteria: absence of any major age-related disease (cancer, CVD, AD, diabetes), preserved functional independence, and no chronic medications. We need n=500 to establish a robust baseline.

We'll contrast this with two standard cohorts: 1) Age-matched individuals with one or more diagnosed age-related diseases, and 2) Healthy young controls (30-40). The goal isn't to find longevity genes. It's to map the ground state of advanced age—the molecular signature of not getting sick.

Current geroscience assumes disease is the inevitable manifestation of aging. What if it's a branch point? What if the nonagenarian phenotype reveals a successfully suppressed developmental program that, in most, gets re-activated by stochastic damage?

We're looking for collaborators. Specifically, access to deep-phenotyped, extremely old, remarkably healthy cohorts. Think super-ager studies, but with stricter exclusion criteria. Also need specialists in chromatin topology and systems immunology to help parse the data.

This requires funding that believes in foundational biology, not just therapeutic pipelines. Who's in?